UCLA Brings Breakthrough Breast Cancer Drug to Patients

Signaling a new treatment strategy for women with breast cancer, the drug IBRANCE (palbociclib) has just been approved by the FDA. Developed over a nearly ten-year period by JCCC researchers Drs. Richard Finn and Dennis Slamon, IBRANCE is the first drug of its class to be approved by the agency and has shown in clinical studies to nearly double progression-free survival in women with estrogen-receptor positive advanced breast cancer. Read more >

In Memory: Research Pioneer Dr. Victor Marder

Join us in mourning Victor Marder, a JCCC member and recognized leader in the field of hematology research, who died January 29 at his home in Los Angeles, California, after a long battle with myelofibrosis complicated by acute leukemia. At the time of his passing, he was seeking to develop effective treatments for acute stroke and working on a therapy with the potential to dissolve clots without the risk of bleeding complications. He is survived by his wife and two daughters. Read more >

Give the Gift of Hope for Valentine's Day

This Valentine's Day, honor a loved one with a gift to support cancer research at the JCCC. It's as easy as 1, 2, 3! Start by giving any amount you wish to the JCCF. Then select one of our new eCards. Finally schedule your eCard to be sent automatically on February 14. Show your loved one how much you care while giving back to fund vital research. Donate now >

Children of Melanoma Survivors Need Better Protection from Sun's Harmful Rays Finds Study

Led by JCCC member Dr. Beth Glenn, new research has found that children of melanoma survivors are not getting enough protection from the sun's harmful rays. The two-year study discovered that these children and their caregivers are not adhering optimally to sun protection recommendations, which is concern as sunburns are a major risk factor for melanoma and can lead to increased risk for developing the disease in adulthood. Read more >

New Research Unlocks How Melanoma Can Resist Newly Approved Drug Combo Therapy

In a new study led by JCCC member Dr. Roger Lo, researcher discovered how melanoma builds up
resistance to normally effective drug therapy combos that utilize BRAF+MEK inhibitors. By analyzing tumor samples from patients before being prescribed the drug therapy and after, Lo and co-author Dr. Antoni Ribas found that drug combo-resistant tumor cells carry highly unusual genetic changes that make the inhibitors ineffective.